Edition:
India

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

1.50USD
15 Dec 2017
Change (% chg)

$0.01 (+0.67%)
Prev Close
$1.49
Open
$1.49
Day's High
$1.50
Day's Low
$1.44
Volume
154,689
Avg. Vol
48,907
52-wk High
$1.67
52-wk Low
$0.92

Latest Key Developments (Source: Significant Developments)

ArQule Files For Offering Of Up To 17.1 Million Shares
Thursday, 7 Dec 2017 

Dec 6 (Reuters) - Arqule Inc ::ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule reports Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arqule Inc :Arqule reports third quarter 2017 financial results.Q3 loss per share $0.09.Sees FY 2017 loss per share $0.38 to $0.40.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍Expects to end 2017 with between $47 and $49 million in cash and marketable securities​.Arqule Inc - ‍For 2017, Arqule expects net use of cash to range between $25 and $27 million​.  Full Article

ArQule announces $9.5 mln private placement of preferred stock
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - ArQule Inc :ArQule announces $9.5 million private placement of preferred stock.ArQule Inc - to use proceeds to advance clinical trials related to proprietary pipeline, including derazantinib, miransertib, ARQ 531 & ARQ 751​.  Full Article

Arqule announces $15.7 mln private placement of common stock
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Arqule Inc :Arqule announces $15.7 million private placement of common stock.Arqule Inc - ‍intends to use net proceeds from offering to advance clinical trials related to its proprietary pipeline​.Arqule Inc - expects in first part of 2019 to obtain arq 531 PK/PD data from phase 1a trial in patients with refractory b-cell malignancies.Arqule inc - ‍company currently anticipates cash and marketable securities to provide funding into 2019​.Arqule Inc - ‍expects to end 2017 with between $38 and $40 million in cash and marketable securities​.Arqule Inc - expects in first part of 2019 to initiate phase 1b proof of concept trial​ for arq 531.Arqule-Expects in first part of 2019 to present authorities with proof of concept data to initiate registrational trial in proteus syndrome​ for ARQ 092.  Full Article

Arqule Inc files for mixed shelf of upto $100 million - SEC filing
Friday, 2 Sep 2016 

Arqule Inc : Files for mixed shelf of upto $100 million - SEC filing Source: (http://bit.ly/2bJGGEw) Further company coverage: [ARQL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Arqule Q2 loss per share $0.07
Wednesday, 3 Aug 2016 

Arqule Inc : Q2 loss per share $0.07 . Q2 earnings per share view $-0.08 -- Thomson Reuters I/B/E/S . Arqule reports second quarter 2016 financial results . Q2 revenue $1.072 million versus i/b/e/s view $1.1 million .Q2 earnings per share view $-0.08, revenue view $1.1 million -- Thomson Reuters I/B/E/S.  Full Article

Arqule Inc gives FY 2016 guidance
Wednesday, 4 May 2016 

Arqule Inc:Expects FY 2016 revenues to range between $4 and $5 million.Expects FY 2016 net loss to range between $24 and $27 million, and net loss per share to range between $(0.34) and $(0.39).  Full Article

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage: